First Parkinson’s Patient Dosed in Pivotal Phase III Cell Therapy Trial

Published on BlueRock Therapeutics

BlueRock Therapeutics has treated the first Parkinson’s disease patient in its pivotal Phase III trial of bemdaneprocel, an investigational stem cell-derived therapy. The trial will evaluate the therapy’s ability to restore dopamine neurons and improve motor function, marking a significant step in advancing regenerative approaches for neurodegenerative disease.

👉 Read the full article: First Parkinson’s Disease Patient Treated in BlueRock’s Pivotal Phase III Trial of Investigational Cell Therapy Bemdaneprocel

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.